Additionally, the integration of mutational profiles across PRDM16 expression levels revealed that PRDM16 expression was lowest in AML patients with TET2/IDH1/2 alterations and concurrent DNMT3A-wildtype status (Fig. 1G). This evidence concerns the gene DNMT3A and acute myeloid leukemia.